July 14, 2025

GLP-1 Use Tied to Reflux Complications

Researchers found that GLP-1 receptor agonists were associated with an increased risk of GERD and related complications in patients with type 2 diabetes.

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 03, 2025

Is Skin Thicker with Vitamin C?

Vitamin C may help thicken human skin by epigenetically activating genes involved in cell growth, according to new research using a lab-grown human skin model. The study found that vitamin C, or L-ascorbic acid, promotes epidermal proliferation by modifying gene activity through DNA demethylation.

Conexiant

June 23, 2025

STING Deletion Attenuates Amyloid Beta Pathology

Genetic deletion of STING in a mouse model of Alzheimer’s disease reduced amyloid plaque accumulation, suppressed neuroinflammatory responses, and improved memory, highlighting STING’s role in disease progression and potential as a therapeutic target.

Conexiant

November 07, 2024

AI in Neuropathology: How Language Models Are Transforming Brain Tumor Diagnosis

New research explores how integrating AI with clinical guidelines can enhance diagnostic precision for complex brain tumors.

Conexiant

May 22, 2025

At-Home HPV Test Matches Clinic Accuracy

Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant